Open access peer-reviewed Edited Volume

Recent Understanding of Colorectal Cancer Treatment

Keun-Yeong Jeong

Metimedi Pharmaceuticals

Dr. Keun-Yeong Jeong developed an atopic dermatitis animal model, promotion method for cancer treatment using stem cell and radiation, and he is a main inventor of OMT-110 which is a major technology of MetiMedi Pharmaceuticals where he serves as the Chief Scientific Officer and the vice president. Dr. Jeong is also a member of the American Association for Cancer Research, American Society of Clinical Oncology, American Society for Nutrition, and the Korean Cancer Association.


Colorectal Cancer Genetic Mutation Carcinogenesis Epigenetics Biomarker Liquid Biopsy Chemotherapy Surgery Immunotherapy Xenograft Tumor Microenvironment Nutrition

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

Colorectal cancer is one of the most common tumors in the adult population. Since the adenocarcinoma sequence was described in the 1970s, the molecular mechanisms involved in the pathogenesis of colorectal cancer have been studied. The study of colorectal cancer is one of the most important in understanding of the mechanisms involved in the development of malignant neoplasms. Several genes, such as RAS, BRAF, PARP, and TP53, have been well identified as participants in carcinogenesis. Also, increasing advances in molecular biology studies are contributing significantly to the understanding of colorectal cancer progression, enabling early detection of premalignant lesions, expanding the possibilities of appropriate diagnosis and prognosis prediction, and further developing efficient therapies. Here, the necessity is raised to construct an up-to-date understanding of this information, which has been established and organized from the past. Accordingly, this book intends to cover a wide range of clinical and non-clinical research topics related to the pathogenesis, diagnosis and prognosis prediction of colorectal cancer, as well as recent therapeutic options.

Publishing process

Book initiated and editor appointed

Date completed: February 2nd 2022

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline Extended: Open for Submissions

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Approved chapters written in full and submitted

Deadline for full chapters: June 4th 2022

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: August 23rd 2022

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: October 22nd 2022

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Keun-Yeong Jeong

Metimedi Pharmaceuticals

Keun-Yeong Jeong serves as the Chief Scientific Officer and the vice president of MetiMedi Pharmaceuticals. He received his MS and Ph.D. in Medicine from the Korea University, and B.S. in Biology from the Chungbuk National University. He completed his postdoctoral fellowship at the Yonsei University Cancer Center. Prior to founding MetiMedi Pharmaceuticals, Dr. Jeong was a Research Professor at the Gachon University where he focused on investigating cancer metabolism and chronic inflammatory diseases. He has noticeable scientific achievements including many peer reviewed publications and patents. Dr. Jeong developed an atopic dermatitis animal model, promotion method for cancer treatment using stem cell and radiation, and he is a main inventor of OMT-110 which is a major technology of MetiMedi Pharmaceuticals.

View profile

Book chapters authored 1

Books edited 1

Introducing your Author Service Manager

Ms. Ana Javor

As an Author Service Manager, my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors, and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question

Book will be abstracted and indexed in